Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 6 minute read Pharma Industry News Could FcRn blockers become the next biologics blockbuster class after interleukin inhibitors and JAKs? A new frontier is emerging in the world of biologic therapies. After years of dominance by interleukin inhibitors… byVenkateshOctober 25, 2025